MediPharm Labs Enters Brazil – Latin America’s Largest Medical Cannabis Market in Partnership with XLR8 Brazil - Seite 3

1)   LATAM Cannabis Report by Prohibition Partners https://prohibitionpartners.com/wp-content/uploads/2019/07/The-LATAM-C ...

About XLR8 Brazil
Headquartered in Rio de Janeiro, XLR8 is a full-service market entry partner for GMP medical cannabis products in Brazil and one of the original pioneering operators in the Brazilian medical cannabis industry. With a focus on differentiated and efficacious products, XLR8 is amongst a small cluster of leading players positioned to take advantage of Brazil’s evolving medical cannabis framework and its focus on clinically validated registered medications.

XLR8 Brazil has previously imported medical cannabis products for compassionate use and submitted all required documentation for the commercial import, storage, distribution and sale of medical cannabis products. Additionally, XLR8 is partnered with strategic resources allowing for immediate importation of compliant medical cannabis products.

About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its Australian extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:

For MediPharm:
Laura Lepore, VP, Investor Relations and Communications
Telephone: [phone] ext. 1525
Email: [e-mail]     
Website: www.medipharmlabs.com    

For XLR8:
Thiago Callado, CEO
Telephone: [phone]
Email: [e-mail]
Website: www.xlr8brazil.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, the successful performance of the agreement and shipping of products thereunder as planned; distribution by XLR8 of products to leading pharmacies and other authorized channels in Brazil; XLR8 obtaining ANVISA product registrations; forecasts regarding the growth and size of the Brazilian market; and providing further support and commercialization for XLR8 in the future. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.